Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Intermediate risk prostate cancer patients will be eligible for this study. Intermediate risk grouping will be assessed per NCCN guidelines as:
Pathologically-proven diagnosis of prostate adenocarcinoma
PSA 10-20ng/mL or
Gleason =7 or
Clinical stage T2b/c
Clinical stage T2b/c Additionally, patients will be required to meet the following criteria
Age ≥18
KPS≥70
Prostate volume ≤ 60cc (cytoreductive androgen deprivation therapy prior to brachytherapy of ≤ 6 months duration will be allowed to achieve this goal). For patients with a prostate volume between 50-60ccs, hormone therapy will be at the discretion of the physician.
International Prostate Symptom Score ≤15
You may not be if
Prior prostate surgery (including TURP)
Prior history of chronic prostatitis or urethral stricture
Inflammatory bowel disease
Prior history of pelvic radiotherapy
Unable to give informed consent
Metastatic disease.
Clareo Health | Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer
